Medicines planning
49 results
Applied filters
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for denosumab 60mg biosimilars
16 January 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.